Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)
HKD 2.14
(-1.83%)
HKD 2.14
(-1.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -158.31 Million CNY | 41.15% |
| 2022 | -209.05 Million CNY | 43.69% |
| 2021 | -477.76 Million CNY | -33.33% |
| 2020 | -358.33 Million CNY | -1698.21% |
| 2019 | - HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -13.8 Million HKD | 56.03% |
| 2024 Q2 | -13.68 Million HKD | 0.15% |
| 2023 Q2 | -48.55 Million HKD | 5.52% |
| 2023 FY | - CNY | 41.15% |
| 2023 Q4 | -32.01 Million HKD | -2.57% |
| 2023 Q3 | -31.21 Million HKD | 35.72% |
| 2023 Q1 | -51.39 Million HKD | 23.32% |
| 2022 Q2 | -139.95 Million HKD | 0.0% |
| 2022 FY | - CNY | 43.69% |
| 2022 Q4 | -67.01 Million HKD | -2.58% |
| 2022 Q3 | -65.33 Million HKD | 53.32% |
| 2021 Q4 | -216.15 Million HKD | 0.0% |
| 2021 Q2 | -261.37 Million HKD | 0.0% |
| 2021 FY | - CNY | -33.33% |
| 2020 FY | - CNY | -1698.21% |
| 2019 FY | - HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 273.523% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 132.521% |